Literature DB >> 30396209

Normocalcemic Primary Hyperparathyroidism: A Comparison with the Hypercalcemic Form in a Tertiary Referral Population.

Jan Pierreux1, Bert Bravenboer1.   

Abstract

Normocalcemic primary hyperparathyroidism (NPHPT) is a formally recognized variant of primary hyperparathyroidism (PHPT), characterized by normal total and ionized serum calcium concentrations and elevated parathyroid hormone (PTH) levels, in the absence of secondary causes for hyperparathyroidism. NPHPT has been studied previously, but data are limited and confounded. We aimed to compare the clinical and biochemical data of normocalcemic and hypercalcemic subjects in a hospital-based population.We retrospectively analysed the medical records of 131 subjects diagnosed with PHPT at the university hospital Brussels (UZ Brussel) between January 1st 2007 and December 31st 2016, including 25 normocalcemic and 106 hypercalcemic subjects.The mean values of age, BMI, sex, serum 25-OH vitamin D levels and urinary phosphate excretion were comparable between both groups. Subjects diagnosed with NPHPT had significantly lower plasma PTH levels, lower urinary calcium excretion and lower serum creatinine levels compared to the hypercalcemic subjects with PHPT. Corresponding eGFR values were higher in the normocalcemic group. Normocalcemic subjects (NPHPT) presented with a high prevalence of nephrolithiasis (36%), fragility fractures (12%) and osteoporosis (25%). Clinical manifestations and BMD measurements revealed no statistically significant differences between both groups.Our data show a relative prevalence of 19% NPHPT in PHPT. NPHPT may present the earliest form of PHPT with an extension in time, but is not an indolent disease state. Normocalcemic subjects should be managed as hypercalcemic subjects with PHPT. Further research regarding the pathophysiology and natural course of NPHPT is required. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30396209     DOI: 10.1055/a-0752-4533

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  5 in total

1.  UPDATE - Canadian Urological Association guideline: Evaluation and medical management of kidney stones.

Authors:  Naeem Bhojani; Jennifer Bjazevic; Brendan Wallace; Linda Lee; Kamaljot S Kaler; Marie Dion; Andrea Cowan; Nabil Sultan; Ben H Chew; Hassan Razvi
Journal:  Can Urol Assoc J       Date:  2022-06       Impact factor: 2.052

2.  PTH induces bone loss via microbial-dependent expansion of intestinal TNF+ T cells and Th17 cells.

Authors:  Mingcan Yu; Abdul Malik Tyagi; Jau-Yi Li; Jonathan Adams; Timothy L Denning; M Neale Weitzmann; Rheinallt M Jones; Roberto Pacifici
Journal:  Nat Commun       Date:  2020-01-24       Impact factor: 14.919

Review 3.  Role of Gut Microbiota in the Skeletal Response to PTH.

Authors:  Roberto Pacifici
Journal:  J Clin Endocrinol Metab       Date:  2021-03-08       Impact factor: 5.958

4.  Parathyroid Hormone Disturbances in Postmenopausal Women with Distal Forearm Fracture.

Authors:  Axel Wihlborg; Karin Bergström; Paul Gerdhem; Ingrid Bergström
Journal:  World J Surg       Date:  2021-10-13       Impact factor: 3.352

5.  Efficacy and Safety of Ultrasound-Guided Radiofrequency Ablation for Primary Hyperparathyroidism: A Prospective Study.

Authors:  Hui-Hui Chai; Yu Zhao; Zeng Zeng; Rui-Zhong Ye; Qiao-Hong Hu; Hong-Feng He; Jung Hwan Baek; Cheng-Zhong Peng
Journal:  Korean J Radiol       Date:  2022-05       Impact factor: 7.109

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.